Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
13 juin 2024 08h00 HE
|
Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
12 juin 2024 16h30 HE
|
Cellectis Inc.
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
12 juin 2024 16h01 HE
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, June 12, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12 juin 2024 16h01 HE
|
Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
Tevogen Bio Set to Join Russell 3000® Index
12 juin 2024 15h45 HE
|
Tevogen Bio Inc
Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.
Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
12 juin 2024 08h00 HE
|
Quoin Pharmaceuticals, Inc.
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles...
浩鼎啟動OBI-992一/二期臨床試驗
12 juin 2024 05h55 HE
|
OBI Pharma Inc.
OBI-992以TROP2為標靶的ADC 研究目的在評估治療多種實體腫瘤的安全性和有效性 台灣台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎 (4174.TWO)今（12）日宣布，正式啟動OBI-992的人體一/二期臨床試驗。OBI-992係浩鼎自行研發，以TROP2為標靶所設計的抗體藥物複合體(antibody-drug conjugate,...
浩鼎启动OBI-992一/二期临床试验
12 juin 2024 05h55 HE
|
OBI Pharma Inc.
OBI-992以TROP2为标靶的ADC 研究目的在评估治疗多种实体肿瘤的安全性和有效性 台湾台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎 (4174.TWO)今（12）日宣布，正式启动OBI-992的人体一/二期临床试验。 OBI-992系浩鼎自行研发，以TROP2为标靶所设计的抗体药物复合体(antibody-drug...
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
12 juin 2024 05h55 HE
|
OBI Pharma Inc.
OBI-992 phase 1/2 study initiation
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
11 juin 2024 15h30 HE
|
Tevogen Bio Inc
Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.